Major trial tests adding new drug to standard myeloma treatment
Disease control
Ongoing
This large study is testing whether adding a new drug called isatuximab to standard treatment improves outcomes for people newly diagnosed with multiple myeloma, a blood cancer. It involves 662 participants who will receive either the standard three-drug combination or that same …
Phase: PHASE3 • Sponsor: University of Heidelberg Medical Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC